Literature DB >> 19428865

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

W Koudstaal1, L Hartgroves, M Havenga, I Legastelois, C Ophorst, M Sieuwerts, D Zuijdgeest, R Vogels, J Custers, E de Boer-Luijtze, O de Leeuw, L Cornelissen, J Goudsmit, W Barclay.   

Abstract

Reverse genetics, the generation of influenza viruses from cDNA, presents a rapid method for creating vaccine strains. The technique necessitates the use of cultured cells. Due to technical and regulatory requirements, the choice of cell lines for production of human influenza vaccines is limited. PER.C6 cells, among the most extensively characterized and documented cells, support growth of all influenza viruses tested to date, and can be grown to high densities in large bioreactors in the absence of serum or micro carriers. Here, the suitability of these cells for the generation of influenza viruses by reverse genetics was investigated. A range of viruses reflective of vaccine strains was rescued exclusively using PER.C6 cells by various transfection methods, including an animal component-free procedure. Furthermore, a whole inactivated vaccine carrying the HA and NA segments of A/HK/156/97 (H5N1) that was both rescued from and propagated on PER.C6 cells, conferred protection in a mouse model. Thus PER.C6 cells provide an attractive platform for generation of influenza vaccine strains via reverse genetics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428865     DOI: 10.1016/j.vaccine.2009.02.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

3.  A small-molecule fusion inhibitor of influenza virus is orally active in mice.

Authors:  Maria J P van Dongen; Rameshwar U Kadam; Jarek Juraszek; Edward Lawson; Boerries Brandenburg; Frederike Schmitz; Wim B G Schepens; Bart Stoops; Harry A van Diepen; Mandy Jongeneelen; Chan Tang; Jan Vermond; Alida van Eijgen-Obregoso Real; Sven Blokland; Divita Garg; Wenli Yu; Wouter Goutier; Ellen Lanckacker; Jaco M Klap; Daniëlle C G Peeters; Jin Wu; Christophe Buyck; Tim H M Jonckers; Dirk Roymans; Peter Roevens; Ronald Vogels; Wouter Koudstaal; Robert H E Friesen; Pierre Raboisson; Dashyant Dhanak; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2019-03-08       Impact factor: 47.728

4.  Vaccine production, distribution, access, and uptake.

Authors:  Jon Smith; Marc Lipsitch; Jeffrey W Almond
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

5.  Genetic content of Influenza H3N2 vaccine seeds.

Authors:  Corinne Bergeron; Martine Valette; Bruno Lina; Michele Ottmann
Journal:  PLoS Curr       Date:  2010-09-05

Review 6.  Many ways to make an influenza virus--review of influenza virus reverse genetics methods.

Authors:  Othmar G Engelhardt
Journal:  Influenza Other Respir Viruses       Date:  2012-06-19       Impact factor: 4.380

7.  Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.

Authors:  Althaf I Hussain; Melissa Cordeiro; Elizabeth Sevilla; Jonathan Liu
Journal:  Vaccine       Date:  2010-03-20       Impact factor: 3.641

Review 8.  RNA virus reverse genetics and vaccine design.

Authors:  Christopher C Stobart; Martin L Moore
Journal:  Viruses       Date:  2014-06-25       Impact factor: 5.048

9.  Development and Validation of Quantitative Real-Time PCR for the Detection of Residual CHO Host Cell DNA and Optimization of Sample Pretreatment Method in Biopharmaceutical Products.

Authors:  Weifeng Zheng; Lin Jiang; Qing Lei; Jun Yang; Xuefeng Gao; Wanru Wang; Yanli Zhang; Tao Kong; Qiaoli Chen; Gang Li
Journal:  Biol Proced Online       Date:  2019-09-01       Impact factor: 3.244

Review 10.  Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.

Authors:  Ana F Rodrigues; Hugo R Soares; Miguel R Guerreiro; Paula M Alves; Ana S Coroadinha
Journal:  Biotechnol J       Date:  2015-07-24       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.